Technology | June 15, 2012

GE Showcases New Technology to Help Assess Earlier Cancer Treatment Response

Effective therapy may help improve the patient’s quality of life and overall outcome as well as reduce the cost burden of ineffective treatment

June 15, 2012 — At the Society of Nuclear Medicine (SNM) 2012, GE Healthcare showcased Q.Suite on both the new Discovery PET/CT 710 and Discovery PET/CT 610 products.  Q.Suite is a collection of next-generation capabilities designed to further quantitative positron emission tomography (PET) by generating more consistent standardized uptake value (SUV) readings — enabling clinicians to assess treatment response accurately, allowing oncologists to modify treatment strategies without waiting for physical results. Effective therapy may help improve the patient’s quality of life and overall outcome as well as reduce the cost burden of ineffective treatment technologies.

The use of PET in therapy assessment is already proven and effective.  But by combining the capabilities of Q.Suite with updated clinical practices, we believe the consistency of PET measurements can increase dramatically.  The goal is a more personalized care for all patients.

During the course of cancer treatment, clinicians traditionally gauge progress by looking for physical change in the size of a tumor, typically using computed tomography (CT) or magnetic resonance (MR). However, with quantitative PET imaging, they are also able to consider a tumor’s metabolic activity. In many cases, metabolic changes in a tumor can be perceived earlier than physical ones, so quantitative PET can give physicians an earlier view of how well a treatment is working.

For quantitative PET to be effective, consistency of SUV measurements between a patient’s baseline scan and subsequent follow-up scans is critical. Variation can occur throughout the PET workflow, in areas from patient management and biology to equipment protocols and performance. Controlling these variables to increase consistency can improve the clinician’s confidence that an SUV change has true clinical meaning.

For more information: www.gehealthcare.com 

Related Content

NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
Improving Molecular Imaging Using a Deep Learning Approach
News | Nuclear Imaging | March 21, 2019
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
News | PET-CT | February 06, 2019
Technological advancements in positron emission tomography/computed tomography (PET/CT) offer both clinicians and pat
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...